De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Biora Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Biora Therapeutics' is Adi Mohanty, benoemd in Nov2021, heeft een ambtstermijn van 2.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.14M, bestaande uit 18.3% salaris en 81.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.03% van de aandelen van het bedrijf, ter waarde € 665.49K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.7 jaar en 3.3 jaar.

Belangrijke informatie

Adi Mohanty

Algemeen directeur

US$3.1m

Totale compensatie

Percentage CEO-salaris	18.3%
Dienstverband CEO	2.9yrs
Eigendom CEO	4.0%
Management gemiddelde ambtstermijn	2.7yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Adi Mohanty's beloning veranderd ten opzichte van Biora Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$87m
Mar 31 2024	n/a	n/a	-US$111m
Dec 31 2023	US$3m	US$574k	-US$124m
Sep 30 2023	n/a	n/a	-US$122m
Jun 30 2023	n/a	n/a	-US$64m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$4m	US$550k	-US$49m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$140m
Mar 31 2022	n/a	n/a	-US$176m
Dec 31 2021	US$10m	US$63k	-US$179m

Compensatie versus markt: De totale vergoeding ($USD 3.14M ) Adi } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 503.65K ).

Compensatie versus inkomsten: De vergoeding van Adi is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Adi Mohanty (57 yo)

2.9yrs

Tenure

US$3,139,017

Compensatie

Mr. Aditya P. Mohanty, also known as Adi,M.B.A. serves as Chief Executive Officer and Director at Biora Therapeutics, Inc. (formerly known as Progenity, Inc.) since November 8, 2021. Mr. Mohanty founded En...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Aditya Mohanty	CEO & Director	2.9yrs	US$3.14m	4.03% $ 702.2k
Eric d'Esparbes	Chief Financial Officer	5.4yrs	US$1.60m	1.58% $ 275.3k
Clarke Neumann	Senior VP	10.1yrs	US$1.53m	1.28% $ 222.6k
Eric Fox	VP of Finance & Accounting & Treasurer	no data	geen gegevens	geen gegevens
George Gianakopoulos	Senior Vice President of Sales	5yrs	geen gegevens	geen gegevens
Robyn Hatton	Head of Human Resources	no data	geen gegevens	geen gegevens
Kevin Howe	Senior VP of Strategic Operations	no data	geen gegevens	geen gegevens
Sharat Singh	Head of Research	2.5yrs	geen gegevens	geen gegevens
Paul Shabram	Head of Technical Operations	2.5yrs	geen gegevens	geen gegevens
Ariella Kelman	Chief Medical Officer	1.4yrs	geen gegevens	geen gegevens
James Knight	Head of Business Development	less than a year	geen gegevens	geen gegevens

2.7yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4ZU0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Aditya Mohanty	CEO & Director	2.9yrs	US$3.14m	4.03% $ 702.2k
Brian Kotzin	Independent Director	5.3yrs	US$185.11k	0.050% $ 8.7k
William Chey	Member of Clinical Advisory Board SIBO & Functional Bowel Disorders	no data	geen gegevens	geen gegevens
Anthony Lembo	Member of Clinical Advisory Board SIBO & Functional Bowel Disorders	no data	geen gegevens	geen gegevens
Geert D'Haens	Member of Inflammatory Bowel Disease Clinical Advisory Board	3.3yrs	geen gegevens	geen gegevens
Bruce Sands	Chairman of Inflammatory Bowel Disease Clinical Advisory Board	3.3yrs	geen gegevens	geen gegevens
Jeffrey Alter	Independent Chairman	5.8yrs	US$208.11k	0.052% $ 9.1k
Mark Pimentel	Member of Clinical Advisory Board - SIBO & Functional Bowel Disorders	no data	geen gegevens	geen gegevens
Lynne Powell	Independent Director	5.7yrs	US$163.11k	0.050% $ 8.7k
Severine Vermeire	Member of Inflammatory Bowel Disease Clinical Advisory Board	3.3yrs	geen gegevens	geen gegevens
Jill Howe	Independent Director	2.9yrs	US$180.11k	0.049% $ 8.5k
Satish Rao	Chair of Clinical Advisory Board-SIBO/Functional Bowel Disorders	no data	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4ZU0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Biora Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Biora Therapeutics, Inc. Appoints Jeffrey A. Ferrell as Director

Biora Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Athyrium Capital Engages in Discussions with Biora Therapeutics

Biora Therapeutics Announces Positive Nasdaq Listing Decision

Athyrium Capital Management Engages with Biora Therapeutics

Biora Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Biora Therapeutics, Inc. Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented At KOL Event

Athyrium Capital Management Engages in Discussions with Biora Therapeutics Inc

Biora Therapeutics, Inc. Announces Positive Clinical Trial Results for BT-600

Biora Therapeutics Provides Non-Compliance Update

Biora Therapeutics, Inc. Appoints Jeffrey A. Ferrell as Director

First quarter 2024 earnings released: US$0.14 loss per share (vs US$1.59 loss in 1Q 2023)

Biora Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose (Mad) Cohorts for Clinical Trial of BT-600

Biora Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development

Athyrium Capital Management Engages in Discussions with Biora Therapeutics

Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $6.000003 million.

Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $6.000003 million.

Full year 2023 earnings released: US$7.88 loss per share (vs US$6.40 loss in FY 2022)

New major risk - Revenue and earnings growth

Biora Therapeutics, Inc. to Report Q4, 2023 Results on Mar 26, 2024

High number of new and inexperienced directors

Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose (Sad) Cohorts of Phase 1 Clinical Study of BT-600

Biora Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Study of BT-600

Athyrium Capital Management Engages in Discussions with Biora Therapeutics

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

Biora Therapeutics, Inc. Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis

Third quarter 2023 earnings released: US$4.89 loss per share (vs US$1.99 loss in 3Q 2022)

Biora Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

High number of new and inexperienced directors

Biora Therapeutics Presents Data on the Biojet™ Systemic Oral Delivery Platform At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Biora Therapeutics, Inc. (NasdaqGM:BIOR) acquired Interface Therapeutics Inc.

Biora Therapeutics Progresses Its BioJet™ Systemic Oral Delivery Platform

First half 2023 earnings released: US$3.01 loss per share (vs US$2.79 loss in 1H 2022)

Biora Therapeutics, Inc. Announces New Patents Covering Its BioJet Systemic Oral Delivery Platform

Biora Therapeutics, Inc. Announces Clinical Device Performance Study Results for its NaviCap Targeted Oral Delivery Platform

New major risk - Shareholder dilution

High number of new and inexperienced directors

Biora Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

An unknown large diagnostics company acquired Legacy Diagnostics Assets of Biora Therapeutics, Inc. (NasdaqGM:BIOR).

Biora Therapeutics Announces New Patents for Its NaviCap Targeted Oral Delivery Platform

Biora Therapeutics Presents Data on the BioJet Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions

Biora Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8 million.

Biora Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Biora Therapeutics Announces Improved Bioavailability Results for Its Systemic Delivery Platform

Biora Therapeutics Receives Compliance Letter from Nasdaq

Biora Therapeutics, Inc. Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress

Biora Therapeutics, Inc. Receives Feedback from the United States Food and Drug Administration on Its Clinical Development Plans for Its Pgn-600 Program

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

Athyrium Capital Engages in Discussions with Biora Therapeutics

Third quarter 2022 earnings released: US$0.08 loss per share (vs US$0.39 loss in 3Q 2021)

High number of new and inexperienced directors

Biora Therapeutics, Inc. has completed a Follow-on Equity Offering.

Biora Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Biora Therapeutics, Inc. Shares Data from Device Performance Study in Ulcerative Colitis Patients

Biora Therapeutics, Inc. Shares Preclinical Data on Oral Delivery of Biologics At the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference

Biora Therapeutics, Inc.Appoints Bruce Sands as Chair of Its Clinical Advisory Board

Second quarter 2022 earnings released: US$0.033 loss per share (vs US$0.65 loss in 2Q 2021)

Biora Therapeutics, Inc. Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for Its Targeted Therapeutics Platform

Biora Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

High number of new and inexperienced directors

Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for Its Targeted Therapeutics Platform

Biora Therapeutics, Inc. Announces Board Appointment

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.30 loss in 1Q 2021)

Biora Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new and inexperienced directors

Progenity, Inc. Announces the Appointment of Paul Shabram as Senior Vice President, Technical Operations

Full year 2021 earnings released: US$1.86 loss per share (vs US$3.83 loss in FY 2020)

Progenity, Inc. Announces Departure of Damon Silvestry